ADAGIO THERAPEUTICS

adagio-therapeutics-logo

Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The companyโ€™s portfolio of antibodies has been optimized using Adimabโ€™s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. ... Adagioโ€™s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with thirdparty contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch.

#SimilarOrganizations #People #Financial #Event #Website #More

ADAGIO THERAPEUTICS

Social Links:

Industry:
Biotechnology Pharmaceutical Therapeutics

Founded:
2020-01-01

Address:
Waltham, Massachusetts, United States

Country:
United States

Website Url:
http://www.adagiotx.com

Total Employee:
51+

Status:
Active

Contact:
781-819-0080

Email Addresses:
[email protected]

Total Funding:
466 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Wordpress Plugins Mobile Non Scaleable Content Microsoft Exchange Online


Similar Organizations

click-therapeutics-logo

Click Therapeutics

Click Therapeutics delivers safe and effective digital treatments to patients in need.

spero-therapeutics-logo

Spero Therapeutics

Spero Therapeutics develops therapeutics for treatment of gram-negative infections.


Current Advisors List

ajay-gopal-royan_image

Ajay Gopal Royan Board Member @ Adagio Therapeutics
Board_member
2020-07-01

terrance-mcguire_image

Terrance McGuire Board Member @ Adagio Therapeutics
Board_member
2020-07-01

philip-chase_image

Philip Chase Board Member @ Adagio Therapeutics
Board_member
2020-07-01

not_available_image

Marc Elia Board Member @ Adagio Therapeutics
Board_member
2020-07-01

Current Employees Featured

tillman-gerngross_image

Tillman Gerngross
Tillman Gerngross Co-Founder and CEO @ Adagio Therapeutics
Co-Founder and CEO

eric-kimble_image

Eric Kimble
Eric Kimble CCO @ Adagio Therapeutics
CCO

ellie-hershberger_image

Ellie Hershberger
Ellie Hershberger CDO @ Adagio Therapeutics
CDO

lynn-connolly_image

Lynn Connolly
Lynn Connolly CMO @ Adagio Therapeutics
CMO

not_available_image

Lawrence Beck
Lawrence Beck Vice President of Finance @ Adagio Therapeutics
Vice President of Finance

halley-gilbert_image

HALLEY GILBERT
HALLEY GILBERT COO & CBO @ Adagio Therapeutics
COO & CBO

not_available_image

Michele Crosby
Michele Crosby Head of Legal & HR Operations @ Adagio Therapeutics
Head of Legal & HR Operations

rebecca-dabora_image

Rebecca Dabora
Rebecca Dabora Chief Technology & Manufacturing Officer @ Adagio Therapeutics
Chief Technology & Manufacturing Officer

david-hering_image

David Hering
David Hering CEO @ Adagio Therapeutics
CEO
2021-07-01

jane-pritchett-henderson_image

Jane Pritchett Henderson
Jane Pritchett Henderson Chief Financial Officer @ Adagio Therapeutics
Chief Financial Officer
2020-12-01

Founder


laura-walker_image

Laura Walker

tillman-gerngross_image

Tillman Gerngross

Stock Details


Company's stock symbol is NASDAQ:ADGI

Investors List

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series C - Adagio Therapeutics

population-health-partners_image

Population Health Partners

Population Health Partners investment in Series C - Adagio Therapeutics

adimab_image

Adimab

Adimab investment in Series C - Adagio Therapeutics

mithril-capital-management_image

Mithril Capital Management

Mithril Capital Management investment in Series C - Adagio Therapeutics

google-ventures_image

GV

GV investment in Series C - Adagio Therapeutics

fidelity-management-and-research-company_image

Fidelity Management and Research Company

Fidelity Management and Research Company investment in Series C - Adagio Therapeutics

redmile-group_image

Redmile Group

Redmile Group investment in Series C - Adagio Therapeutics

foresite-capital_image

Foresite Capital

Foresite Capital investment in Series C - Adagio Therapeutics

polaris-partners_image

Polaris Partners

Polaris Partners investment in Series C - Adagio Therapeutics

arrowpoint-partners_image

ArrowMark Partners

ArrowMark Partners investment in Series C - Adagio Therapeutics

Official Site Inspections

http://www.adagiotx.com Semrush global rank: 3.47 M Semrush visits lastest month: 4.37 K

  • Host name: f3.68.7e4b.ip4.static.sl-reverse.com
  • IP address: 75.126.104.243
  • Location: Dallas United States
  • Latitude: 32.9379
  • Longitude: -96.8384
  • Metro Code: 623
  • Timezone: America/Chicago
  • Postal: 75244

Loading ...

More informations about "Adagio Therapeutics"

Adagio Therapeutics Announces Dosing of First Patient โ€ฆ

Feb 16, 2021 WALTHAM, Mass.--(BUSINESS WIRE)--Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced the initiation of a ...See details»

EX-99.1 - SEC.gov

Prior to his most recent role at Pfizer, Mr. Hering was president, North America at Pfizer, where he led a 700-person organization across a portfolio of vaccine products for COVID-19 and โ€ฆSee details»

Adagio enters a crowded field - TSI Wealth Network

ADAGIO THERAPEUTICS INC. $27 is a hold. The company (Nasdaq symbol ADGI; Manufacturing sector; Shares outstanding: 108.5 million; Market cap: $2.9 billion; No dividend โ€ฆSee details»

Adagio Announces Results of Annual Meeting of Stockholders and ...

Jul 1, 2022 Marc Elia Named Chair of the Board of DirectorsWALTHAM, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage โ€ฆSee details»

Adagio Therapeutics Announces New In Vitro Data Highlighting โ€ฆ

Oct 19, 2021 Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial โ€ฆSee details»

Adagio Announces Results of Annual Meeting of Stockholders

Jul 1, 2022 For more information, please visit www.adagiotx.com. Cautionary Note Regarding Forward Looking Statements This press release contains forward-looking statements within โ€ฆSee details»

Adagio Therapeutics Announces ADG20 Development Plans and

Feb 22, 2022 The safety and efficacy of ADG20 have not been established. For more information, please visit www.adagiotx.com. Forward Looking Statements .See details»

Adagio Therapeutics Summarizes ADG20 Neutralizing Activity โ€ฆ

Jan 12, 2022 Recent Publications by Several Independent Laboratories Show ADG20 Has Neutralizing Activity with Potency Comparable to Other Antibodies that Retain Activity Against โ€ฆSee details»

Adagio Therapeutics Initiates Global Clinical Trial of ADG20 as a ...

Apr 13, 2021 WALTHAM, Mass.--(BUSINESS WIRE)--Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize โ€ฆSee details»

Adagiotx.com Antibody-based therapies to address evolving

Organization: Location: Issuer: E6 Valid from: Nov 14 04:21:08 2024 GMT Valid until: Feb 12 04:21:07 2025 GMT Authority: CA:FALSE Keysize: Common Name: E6 ... Domain Name: โ€ฆSee details»

Adagio Therapeutics to Present at the 40th Annual J.P.

Jan 6, 2022 A live webcast will be available in the investor section of the company's website at investors.adagiotx.com and will be archived for 60 days following the presentations. About โ€ฆSee details»

Adagio Therapeutics to Participate in Upcoming Investor โ€ฆ

Sep 6, 2022 A live webcast of the fireside chat will be available in the investor section of the company's website at investors.adagiotx.com and will be archived for 90 days following the โ€ฆSee details»

Adagio Therapeutics Announces $336 Million Series C Financing to ...

Apr 19, 2021 Adagio Therapeutics Announces $336M Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for Treatment and Prevention of COVID-19See details»

Adagio Therapeutics Reports Second Quarter 2022 Financial โ€ฆ

For more information, please visit www.adagiotx.com. Cautionary Note Regarding Forward Looking Statements This press release contains forward-looking statements within the โ€ฆSee details»

Adagio Therapeutics Appoints David Hering, Global COVID-19

Waltham, MA โ€“ July 19, 2021 โ€“ Adagio Therapeutics, Inc., a biotechnology company developing highly differentiated antibodies to broadly neutralize coronaviruses, today announced that โ€ฆSee details»

Adagio Therapeutics Appoints David Hering, Global COVID-19 โ€ฆ

Jul 19, 2021 Prior to his most recent role at Pfizer, Mr. Hering was president, North America at Pfizer, where he led a 700-person organization across a portfolio of vaccine products in โ€ฆSee details»

Antibody-based therapies to address evolving viral threats | Invivyd

Nov 14, 2024 OUR INVYMABโ„ข PLATFORM. Leveraging state-of-the-art viral surveillance, predictive modeling, and advanced antibody engineering techniques, we are taking a platform โ€ฆSee details»

Adagio Therapeutics Provides Update for ADG20 COVID-19

Nov 15, 2021 September 30, 2021 December 31, 2020 Assets Current assets: Cash and cash equivalents $ 478,269 $ 114,988 Marketable securitiesSee details»

Organization: Invivyd - Cbonds.com

11/04/2024: Invivyd: Item 9.01, Financial Statements And Exhibits: 04/04/2024: Invivyd: On April 4, 2024, The Company Also Posted An Updated Corporate Presentation On Its Website At โ€ฆSee details»

Adagio Therapeutics Announces ADG20 Phase 1 Data and โ€ฆ

May 5, 2021 Preliminary Data from Ongoing Phase 1 Trial in Healthy Volunteers Support ADG20 Safety and Pharmacokinetic Profile and SARS-CoV-2 Neutralizing Activity. Phase 2/3 โ€ฆSee details»

linkstock.net © 2022. All rights reserved